Safety Profile of Biological Medicines as Compared with Non-Biologicals: An Analysis of the Italian Spontaneous Reporting System Database

Drug Safety

Volumn 37, Issue 11, 2014, Pages 961-970

  Cutroneo, Paola M ^a   Isgrò, Valentina ^a   Russo, Alessandra ^a   Ientile, Valentina ^a   Sottosanti, Laura ^b   Pimpinella, Giuseppe ^b   Conforti, Anita ^c   Moretti, Ugo ^c   Caputi, Achille P ^a   Trifirò, Gianluca ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b ITALIAN MEDICINES AGENCY   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BEVACIZUMAB; BIOLOGICAL PRODUCT; BIOSIMILAR AGENT; BLOOD CLOTTING FACTOR; CETUXIMAB; CYTOKINE; ENZYME; ETANERCEPT; HORMONE DERIVATIVE; HUMAN GROWTH HORMONE; HYBRID PROTEIN; INSULIN GLARGINE; INTERFERON; MONOCLONAL ANTIBODY; NATALIZUMAB; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; BREAST DISEASE; COMPARATIVE STUDY; CONNECTIVE TISSUE DISEASE; CYST; DATA BASE; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EAR DISEASE; ENDOCRINE DISEASE; EYE DISEASE; FEMALE; GASTROINTESTINAL DISEASE; GENITAL SYSTEM DISEASE; HEART DISEASE; HEMATOLOGIC DISEASE; HEPATOBILIARY DISEASE; HUMAN; HYPOGLYCEMIA; IMMUNOPATHOLOGY; INFECTION; INFESTATION; INNER EAR DISEASE; ITALY; KIDNEY DISEASE; LYMPHATIC SYSTEM DISEASE; MALE; MEDIASTINUM DISEASE; MENTAL DISEASE; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; NEOPLASM; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; POLYP; RESPIRATORY TRACT DISEASE; SKIN TOXICITY; SPONTANEOUS ABORTION; SUBCUTANEOUS TISSUE; THORAX DISEASE; THYROID DISEASE; URINARY DYSFUNCTION; VASCULAR DISEASE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FACTUAL DATABASE; RISK ASSESSMENT;

ADVERSE DRUG REACTION REPORTING SYSTEMS; BIOSIMILAR PHARMACEUTICALS; DATABASES, FACTUAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; ITALY; RISK ASSESSMENT;

EID: 84911397177     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-014-0224-1     Document Type: Article

References (22)

1. Coordination Group for Mutual Recognition and Decentralised Procedures. Questions & answers biologicals. CMDh/269/2012, October 2012. http://www.hma.eu. Accessed 30 July 2014.
2. European Medicinal Agency. Questions and answers on biosimilar medicines (similar biological medicinal products) 2012. EMA/837805/2011. http://www.ema.europa.eu. Accessed 30 July 2014.
3. Giezen TJ, Mantel-Teeuwisse AK, Leufkens HGM. Pharmacovigilance of biopharmaceuticals. Drug Saf. 2009;32(10):811–7.
4. Giezen TJ, Mantel-Teeuwisse AK, Straus SMJM, Schellekens H, Leufkens HG, Egberts AC. Safety-related regulatory actions for biologicals approved in the United States and the European Union. JAMA. 2008;300(16):1887–96.
5. European Medicines Agency, Heads of Medicines Agencies. Guideline on good pharmacovigilance practices (GVP)—module VI 2012. EMA/873138/2011. http://www.ema.europa.eu. Accessed 30 July 2014.
6. Simoens S. Biosimilar medicines and cost-effectiveness. ClinicoEcon Outcomes Res. 2011;3:29–36.
7. Giezen TJ, Mantel-Teeuwisse AK, Meyboom RHB, Straus SMJM, Leufkens HGM, Egberts TCG. Mapping the safety profile of biologicals. A disproportionality analysis using the WHO Adverse Drug Reaction Database, VigiBase. Drug Saf. 2010;33:865–78.
8. Vermeer NS, Straus SMJM, Mantel-Teeuwisse AK, Domergue F, Egberts TCG, Leufkens HGM, De Bruin ML. Traceability of biopharmaceuticals in spontaneous reporting systems: a cross-sectional study in the FDA Adverse Event Reporting System (FAERS) and EudraVigilance Databases. Drug Saf. 2013;36:617–25.
9. Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti TNF-alpha agents. JAMA. 2009;301(7):737–44.
10. Listing J, Strangfeld A, Kary S, Rau R, Von Hinueber U, Stoyanova-Scholz M, Gromnica-Ihle E, Antoni C, Herzer P, Kekow J, Schneider M, Zink A. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005;52(11):3403–12.
11. Meyboom RH, Star K, Bate J, Savage R, Edwards IR. TNF-a inhibitors and leukaemia: international pharmacovigilance reports. Drug Saf. 2008;31(5):445–7.
12. Sandberg-Wollheim M, Alteri E, Stam Moraga M, Kornmann G. Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy. Mult Scler J. 2011;17(4):423–30.
13. Lu E, Wang BW, Guimond C, Synnes A, Sadovnick D, Tremlett H. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. Neurology. 2012;79(11):1130–5.
14. Cristiano LM, Bozic C, Bloomgren G. Preliminary evaluation of pregnancy outcomes from the Tysabri (natalizumab) pregnancy exposure registry. Mult Scler. 2011;17(suppl 10):A457 (Abstract).
15. Italian Medines Agency. AIFA Position Paper. I farmaci biosimilari. 2013. http://www.agenziafarmaco.gov.it/sites/default/files/AIFA_POSITION_PAPER_FARMACI_BIOSIMILARI.pdf. Accessed 30 July 2014.
16. Loiacono C, Sgroi C, Coppolino S, Cannata A, Ferrara R, Arcoraci V, Cananzi P, Savica V, Schuemie M, Caputi AP, Trifirò G. How much are biosimilars used in Southern Italy? A retrospective analysis of epoetin utilization in the Local Health Unit of Messina in the Years 2010–2011.
17. Agenzia Italiana del Farmaco. L’uso dei farmaci in Italia. Rapporto Nazionale Anno. 2012.http://www.agenziafarmaco.gov.it/it/content/osservatorio-sull%E2%80%99impiego-dei-medicinali-osmed. Accessed 5 February 2014.
18. Agenzia Italiana del Farmaco. L’uso dei farmaci in Italia. Rapporto Nazionale Anno. 2013. http://www.agenziafarmaco.gov.it/it/content/osservatorio-sull%E2%80%99impiego-dei-medicinali-osmed. Accessed 28 July 2014.
19. Gagne JJ, Bykov K. On analyzing therapeutic ineffectiveness reports. Pharmacoepidemiol Drug Saf. 2013;22:207–8.
20. Calvo B, Zuñiga L. EU’s New Pharmacovigilance Legislation: considerations for biosimilars. Drug Saf. 2014;37:9–18.
21. Vonberg RP, Gastmeier P. Hospital-acquired infections related to contaminated substances. J Hosp Infect. 2007;65(1):15–23.
22. Thorpe SJ, Fox BJ, Dolman CD, Lawrence J, Thorpe R. Batches of intravenous immunoglobulin associated with adverse reactions in recipients contain atypically high anti-Rh D activity. Vox Sang. 2003;85(2):80–4.